[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 68 of about 68
5. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist; 2001;6 Suppl 2:22-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hematologic malignancies, such as acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma.
  • The safety and pharmacokinetics of arsenic trioxide are also being evaluated in pediatric patients with refractory leukemia and lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Clinical Trials as Topic. Hematologic Neoplasms / drug therapy. Oxides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331437.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 27
  •  go-up   go-down


6. Bernard MP, Bancos S, Sime PJ, Phipps RP: Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des; 2008;14(21):2051-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase-2 (Cox-2), a key modulator of inflammation.
  • For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):305-15 [14970279.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):128-40 [15059134.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):328-33 [15145323.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):825-30 [15170663.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):425-33 [15621834.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2619-26 [15728468.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2504-9 [15454489.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):31-43 [15911099.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4784-91 [15731178.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):753-6 [16019514.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5504-14 [16061867.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):571-82 [15846081.001]
  • [Cites] Cancer Immunol Immunother. 2005 Oct;54(10):981-7 [15891886.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):212-20 [16104877.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1628-33 [16015389.001]
  • [Cites] Am J Hematol. 2005 Nov;80(3):169-73 [16247750.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1599-607 [16314473.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4330-8 [16123214.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1568-74 [16342649.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76 [16399588.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1114-22 [16424048.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3321-8 [16338931.001]
  • [Cites] BMC Cancer. 2006;6:27 [16445867.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S289-92 [16507395.001]
  • [Cites] Cancer Detect Prev. 2006;30(1):99-101 [16495019.001]
  • [Cites] Mol Carcinog. 2006 Apr;45(4):250-9 [16385588.001]
  • [Cites] Am J Hematol. 2006 Apr;81(4):242-55 [16550520.001]
  • [Cites] Semin Immunol. 2006 Jun;18(3):186-92 [16737823.001]
  • [Cites] Clin Immunol. 2006 Jul;120(1):76-90 [16473553.001]
  • [Cites] Swiss Med Wkly. 2006 Jun 24;136(25-26):400-3 [16847764.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):349-50 [16848779.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(11):1581-90 [16797965.001]
  • [Cites] Immunol Invest. 2006;35(3-4):297-325 [16916756.001]
  • [Cites] Am J Epidemiol. 2006 Sep 1;164(5):497-504 [16840523.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1095-101 [17016639.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1863-71 [17064999.001]
  • [Cites] Leuk Res. 2000 May;24(5):385-92 [10785260.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3111-6 [10955791.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4629-37 [10969817.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):705-12 [11267984.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):94-102 [11841401.001]
  • [Cites] Trends Immunol. 2002 Mar;23(3):144-50 [11864843.001]
  • [Cites] Leukemia. 2002 May;16(5):791-8 [11986939.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):817-20 [12181051.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):38-45 [12358901.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):221-32 [12538661.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):96-102 [12559775.001]
  • [Cites] Am J Epidemiol. 2003 Mar 15;157(6):510-6 [12631540.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E14 [17134116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):31-8 [17049184.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):547-51 [16962170.001]
  • [Cites] Inflammopharmacology. 2007 Feb;15(1):1-4 [17323186.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] Rheumatology (Oxford). 2007 Apr;46(4):690-4 [17148471.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jan;1095:99-112 [17404023.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):269-75 [17224647.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):95-105 [17315190.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):327-34 [17537668.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):247-56 [18231910.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] BMC Cancer. 2008;8:4 [18190720.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 [15179620.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4309-18 [15205346.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1862-6 [15222024.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1395-9 [15359639.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1495-6 [15359658.001]
  • [Cites] Cancer Lett. 2004 Nov 8;215(1):1-20 [15374627.001]
  • [Cites] Clin Exp Immunol. 1983 Jan;51(1):61-8 [6572580.001]
  • [Cites] J Immunol. 1983 Oct;131(4):1734-41 [6604751.001]
  • [Cites] Acta Haematol. 1985;74(3):132-6 [3938156.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4652-8 [2940298.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Surg Today. 1995;25(11):954-8 [8640020.001]
  • [Cites] Blood. 1997 Jul 1;90(1):260-9 [9207461.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):455-9 [10226582.001]
  • [Cites] Stem Cells Dev. 2004 Oct;13(5):484-95 [15588506.001]
  • [Cites] Int J Biol Sci. 2007;3(5):328-34 [17589567.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):878-83 [17450522.001]
  • [Cites] Subcell Biochem. 2007;42:93-126 [17612047.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):705-10 [17546626.001]
  • [Cites] Clin Immunol. 2007 Nov;125(2):138-48 [17728187.001]
  • [Cites] Clin Exp Med. 2007 Sep;7(3):83-97 [17972050.001]
  • [Cites] Am J Pathol. 2007 Nov;171(5):1538-48 [17823287.001]
  • [Cites] Mol Carcinog. 2007 Dec;46(12):971-80 [17477358.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2512-8 [17713545.001]
  • [Cites] Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15 [18056932.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Cancer Immunol Immunother. 2008 Mar;57(3):347-58 [17668203.001]
  • [Cites] Ann Hematol. 2008 Feb;87(2):121-9 [17999062.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):60-7 [18181047.001]
  • [Cites] Mol Ther. 2008 Feb;16(2):269-79 [18071334.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1418-23 [10581086.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11397-403 [10753955.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):469-79 [12734098.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):534-7 [12814999.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):784-8 [12866040.001]
  • [Cites] Leuk Res. 2004 Feb;28(2):179-90 [14654083.001]
  • (PMID = 18691115.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL088325; United States / NIDCR NIH HHS / DE / DE007202-16; United States / NIDCR NIH HHS / DE / T32-DE007202; United States / NHLBI NIH HHS / HL / HL075432; United States / NEI NIH HHS / EY / EY017123; United States / NIDCR NIH HHS / DE / DE011390; United States / NHLBI NIH HHS / HL / R01 HL088325; United States / NIAID NIH HHS / AI / AI071064-02; United States / NIDCR NIH HHS / DE / R01 DE011390; United States / NIAID NIH HHS / AI / AI071064; United States / NIAID NIH HHS / AI / R21 AI071064-02; United States / NHLBI NIH HHS / HL / HL075432-03; United States / NIAID NIH HHS / AI / R21 AI071064; United States / NHLBI NIH HHS / HL / R01 HL075432; United States / NHLBI NIH HHS / HL / R01 HL088325-02; United States / NIDCR NIH HHS / DE / T32 DE007202; United States / NHLBI NIH HHS / HL / R01 HL075432-03; United States / NIDCR NIH HHS / DE / T32 DE007202-16; United States / NHLBI NIH HHS / HL / HL088325-02; United States / NHLBI NIH HHS / HL / T32 HL066988
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 111
  • [Other-IDs] NLM/ NIHMS137022; NLM/ PMC2745246
  •  go-up   go-down


7. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA: Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med; 2008 Feb;22(2):111-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
  • OBJECTIVE: The objective of this study was to evaluate the prevalence and positron emission tomography (PET) imaging features of pulmonary drug toxicity in patients with lymphoma during or just following chemotherapy.
  • METHODS: A total of 677 PET scans on 460 patients with lymphoma (351 non-Hodgkin's lymphoma, 92 Hodgkin's disease, and 17 both Hodgkin's and non-Hodgkin's lymphoma) were performed for the evaluation of chemotherapy response.
  • A review of medical records, (18)fluorodeoxyglucose ((18)FDG)-PET scans, and chest computed tomography (CT) was performed, and cases with probable drug toxicity were identified.
  • Inclusion criteria of probable drug toxicity were abnormal but symmetrical FDG accumulation in both lungs seen during or just following the completion of chemotherapy, the abnormal accumulation or corresponding abnormal CT findings resolved on subsequent studies, exclusion of clinical diagnosis of pneumonia, radiation pneumonitis, or lymphoma involvement.
  • RESULTS: In 10 patients (six men and four women, average age 47.3), 2.2% of cases, probable drug toxicity was identified.
  • CONCLUSIONS: Diffuse and peripheral-dominant FDG accumulation in the lung, which may represent pulmonary drug toxicity, was not uncommon in patients with lymphoma who underwent chemotherapy.
  • FDG-PET scan might be able to detect pulmonary drug toxicity in asymptomatic patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Drug-Related Side Effects and Adverse Reactions / radionuclide imaging. Lung / drug effects. Lung / radionuclide imaging. Lymphoma / drug therapy. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Male. Middle Aged. Radiopharmaceuticals / pharmacokinetics. Thorax / drug effects. Thorax / radionuclide imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311535.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI: Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS; 2007 Sep 12;21(14):1957-63
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare rates of AIDS-defining and non-AIDS-defining malignancies between patients on a CD4 T-cell-guided antiretroviral therapy (ART) strategy and continuous ART.
  • METHODS: Malignancy rates were compared between the drug conservation arm in which ART was stopped if the CD4 T-cell count exceeded 350 cells/microl and (re)started if it fell to less than 250 cells/microl and the viral suppression arm utilizing continuous ART.
  • RESULTS: A total of 5472 participants were randomly assigned to treatment groups, of whom 70 developed cancer: 13 AIDS-defining malignancies and 58 non-AIDS-defining malignancies (one patient had both).
  • The AIDS-defining malignancy rate per 1000 person-years was higher in the drug conservation arm (3.0 versus 0.5).
  • The drug conservation arm also had higher rates of Kaposi's sarcoma (1.9 versus 0.3) and lymphoma (Hodgkin's and non-Hodgkin's; 1.1 versus 0.3).
  • The non-AIDS-defining malignancy rate was similar between the drug conservation and viral suppression arms (8.8 versus 7.1).
  • The most common non-AIDS-defining malignancies were skin (n = 16), lung (n = 8) and prostate (n = 6) cancers.
  • CONCLUSION: Non-AIDS-defining malignancies were more common in this cohort than AIDS-defining malignancies.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. HIV Infections / drug therapy. Neoplasms / etiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Adult. CD4 Lymphocyte Count. Cohort Studies. Female. Humans. Incidence. Lung Neoplasms / epidemiology. Lung Neoplasms / etiology. Lymphoma / epidemiology. Lymphoma / etiology. Male. Middle Aged. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / etiology. RNA, Viral / analysis. Recurrence. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / etiology. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721103.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01AI042170; United States / NIAID NIH HHS / AI / U01AI46362
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / RNA, Viral
  •  go-up   go-down


9. Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, Maranhão RC: Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol; 2006 May;57(5):624-30
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE.
  • Thus, it is possible to use LDL or cholesterol-rich microemulsions (LDE) that bind to LDL receptors as carriers of antineoplastic agents to concentrate those drugs into cancer tissues.
  • PATIENTS AND METHODS: The LDE labeled with [(3) H]-cholesteryl oleate was injected into four Hodgkin's and 12 non-Hodgkin's lymphoma patients and into 16 healthy control subjects and the LDE plasma residence time (RT) was determined from sequential plasma samples.
  • Two volunteers with relapsed/refractory lymphoma were treated with 300 mg/m(2) body surface etoposide associated with LDE in six cycles at 3-week intervals.
  • RESULTS: The LDL cholesterol was lower in lymphoma patients than in controls (94+/-52 and 115+/-16 mg/dL, p=0.0362, respectively).
  • The LDE RT was 49% smaller in lymphoma patients than in controls (RT=21.9 and 45.7 h; p=0.0134), with positive correlation between RT and LDL cholesterol.
  • CONCLUSIONS: Our results suggest that lymphomas overexpress LDL receptors that make room for using LDE as drug-targeting vehicle and that the LDE-etoposide preparation is suitable for patient use.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / toxicity. Cholesterol Esters / pharmacokinetics. Etoposide / toxicity. Hodgkin Disease / metabolism. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cholesterol, LDL / metabolism. Drug Carriers / administration & dosage. Drug Carriers / metabolism. Drug Carriers / pharmacokinetics. Emulsions. Female. Humans. Kinetics. Male. Metabolic Clearance Rate. Middle Aged. Pilot Projects. Receptors, LDL / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133527.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cholesterol Esters; 0 / Cholesterol, LDL; 0 / Drug Carriers; 0 / Emulsions; 0 / Receptors, LDL; 3DPK9KFN2M / cholesteryl oleate; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


10. Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O'Connor OA: A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther; 2009 Aug;86(2):190-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
  • Preliminary evaluations of the pharmacokinetics of the drug and its association with mucositis suggested that pralatrexate exposure (area under the concentration-time curve (AUC)) could be controlled with body size (e.g., weight or body surface area)-based dosing and that pretreatment with folic acid and vitamin B(12) might diminish the incidence and severity of mucositis.
  • [MeSH-major] Aminopterin / analogs & derivatives. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Body Size. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mucositis / prevention & control
  • [MeSH-minor] Adult. Aged. Area Under Curve. Biomarkers / blood. Drug Administration Schedule. Female. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / pharmacology. Humans. Incidence. Male. Methylmalonic Acid. Middle Aged. Models, Statistical. Predictive Value of Tests. Recurrence. Severity of Illness Index. Vitamin B 12 / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474785.001).
  • [ISSN] 1532-6535
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1UL1RR024156; United States / FDA HHS / FD / R01 FD0003498-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Folic Acid Antagonists; 8LL8S712J7 / Methylmalonic Acid; JYB41CTM2Q / Aminopterin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


11. Okamoto R: [Malignant lymphoma]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2532-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma].
  • FDG-PET has technical limitations, variability of FDG avidity among different lymphoma histologic subtypes, and in a large number of etiologies shows false-negative and false positive results.
  • Most studies of FDG-PET involve patients with Hodgkin's disease or diffuse large B-cell lymphoma.
  • FDG PET in lymphoma is being incorporated into the response assessment in lymphoma as published by the Imaging Subcommittee of International Harmonization Project in Lymphoma.
  • New guidelines, the Revised Response Criteria for Malignant Lymphoma, are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma.
  • PET as a biomarker has the potential to change the current model of drug development.
  • [MeSH-major] Lymphoma / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009452.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G: AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant; 2008 Feb;41(4):331-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
  • AMD3100 given with G-CSF has been shown to mobilize CD34+ cells in non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and Hodgkin's disease (HD) patients who could not collect sufficient cells for autologous transplant following other mobilization regimens.
  • There were no drug-related serious adverse events.
  • [MeSH-minor] Adult. Aged. Drug Synergism. Drug Therapy, Combination. Female. Graft Survival. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Middle Aged. Prospective Studies. Transplantation, Autologous / methods

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17994119.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Colony-Stimulating Factors; 0 / Heterocyclic Compounds; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 155148-31-5 / JM 3100
  •  go-up   go-down


13. Curran MP, Goa KL: Pegfilgrastim. Drugs; 2002;62(8):1207-13; discussion 1214-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pegfilgrastim increases the terminal elimination half-life and decreases the apparent serum clearance of the drug in patients with nonmyeloid cancer.
  • In phase III trials in patients with breast cancer and in a phase II trial in patients with non-Hodgkin's lymphoma or Hodgkin's disease, the mean duration of grade 4 neutropenia and the time to absolute neutrophil recovery during cycle 1 of chemotherapy was similar in recipients of single-dose pegfilgrastim or daily filgrastim.
  • In the larger of two phase III trials in patients with breast cancer, the incidence of febrile neutropenia over four cycles of chemotherapy was significantly lower in recipients of single-dose pegfilgrastim than that in recipients of daily injections of filgrastim.
  • Moreover, the mean duration of grade 4 neutropenia in cycles 2 to 4 of chemotherapy was significantly lower in recipients of pegfilgrastim than that in recipients of daily filgrastim.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / pharmacokinetics. Granulocyte Colony-Stimulating Factor / pharmacology. Neutropenia / drug therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Filgrastim. Half-Life. Hodgkin Disease / drug therapy. Humans. Immunocompromised Host. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms / drug therapy. Pain / chemically induced. Recombinant Proteins

  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):727-31 [11821454.001]
  • [Cites] Drugs. 1994 Nov;48(5):731-60 [7530630.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1323-32 [8469254.001]
  • [Cites] Oncology (Williston Park). 1999 May;13(5A):197-257 [10370929.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304 [1458545.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2085-90 [11448927.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2522-8 [10893282.001]
  • [Cites] Exp Hematol. 1999 Dec;27(12):1724-34 [10641590.001]
  • [Cites] Pharmacoeconomics. 1996 Jan;9(1):76-96 [10161371.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):638-46 [10997976.001]
  • (PMID = 12010086.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  • [Number-of-references] 17
  •  go-up   go-down


1
Advertisement
4. Crawford J: Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy; 2003 Aug;23(8 Pt 2):15S-19S
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pegfilgrastim is a long-acting G-CSF, recently approved by the Food and Drug Administration.
  • The efficacy and safety of pegfilgrastim administered once/chemotherapy cycle have been evaluated in clinical trials involving patients treated with myelosuppressive chemotherapy for breast cancer, lung cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Granulocyte Colony-Stimulating Factor / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use. Neutropenia / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Filgrastim. Humans. Recombinant Proteins

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12921218.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  • [Number-of-references] 20
  •  go-up   go-down


15. O'Connor OA: Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl; 2005 Jul;(66):150-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing new drugs for the treatment of lymphoma.
  • Despite the great progress that has been made over the last several decades in the treatment of lymphoma, the prognosis for patients with relapsed disease, and particular sub-types of lymphoma like mantle cell and T cell lymphoma, remains quite poor.
  • While major advances in the use of combination chemotherapy, monoclonal antibodies, peripheral blood stem cell transplants, and radioimmunotherapy, have provided new opportunities to alter the natural history of these diseases, and even improve cure rates among elected sub-populations of patients, these 'traditional' approaches have not benefited all patients, or subtypes of lymphoma.
  • The incredibly rapid pace of understanding the molecular basis for the discrete sub-types of both non-Hodgkin's lymphoma and Hodgkin's Disease is beginning to afford exciting new opportunities to both risk stratify patients, and to identify potentially novel 'drugable' targets.
  • These advancements in understanding the major molecular defects in lymphoma, have provided a new context in which we can rethink the use of new and old drugs, and design new ones with unique mechanisms of action.
  • The panoply of new targets and drugs now becoming available for the treatment of lymphoma is truly daunting.
  • In many cases, the empirical observations from early clinical trials have provided invaluable clues to potentially valuable drugs like bortezomib, depsipeptide, and SAHA, These empirical observations, based on the inclusion of patients with lymphoma on these studies, have thus far proven to be as or more valuable than any other 'rational' target based approach.
  • In addition, beyond the novel small molecules affecting unique and heretofore unrecognized biological pathways, there continues to be a robust and important effort to identify new derivatives of older generation drugs with hopefully better activity, and less toxicity.
  • For example, new generation anthracenediones and anti-folates, and new formations of older drugs like doxorubicin, irinotecan, and vincristine afford new opportunities to favourably change the pharmacokinetic profile of these agents, and improve their overall safety profile.
  • While it would not be possible to address each and every new such drug, we hope to touch on some of the major new themes and agents emerging for the treatment of Hodgkin's Disease and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Drug Design. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007885.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA 69913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 41
  •  go-up   go-down


16. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF: Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol; 2003;14 Suppl 1:i11-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
  • We have treated 38 transplant-eligible patients with relapsed/refractory non-Hodgkin's lymphoma and Hodgkin's disease using an outpatient-based regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and peripheral blood stem cell mobilisation.
  • Patients included relapsed or refractory diffuse large B-cell lymphoma (n = 17), follicular lymphoma (n = II), T-cell lymphoma (n = 2), mantle cell lymphoma (n = 2) and Hodgkin's disease (n = 6).
  • Seven patients with diffuse large B-cell lymphoma and three patients with follicular lymphoma (26%) were considered chemorefractory.
  • Of the I I follicular lymphoma patients, 10 also received rituximab with ICE therapy.
  • There were no toxic deaths and no significant non-haematological toxicities secondary to ICE therapy.
  • Grade IV thrombocytopenia and grade IV neutropenia with at least one cycle of ICE were seen in 47% and 53% of patients, respectively.
  • comprising 14 patients (37%) who achieved a complete response (CR) and 19 (50%) who achieved a partial response (PR).
  • A total of 30 patients have undergone autologous stem cell transplantation(SCT) while two follicular lymphoma patients have received a non-myeloablative allogeneic SCT.
  • Event-free survival for patients who achieved a CR after ICE and transplantation is 88% versus 45% for those who achieved a PR.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12736225.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


17. Koeppen S, Verstappen CC, Körte R, Scheulen ME, Strumberg D, Postma TJ, Heimans JJ, Huijgens PC, Kiburg B, Renzing-Köhler K, Diener HC: Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2004 Mar;130(3):153-60
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.
  • PURPOSE: This randomized, double-blind, placebo-controlled study evaluates the effect of the corticotropin (4-9) analogue Org 2766 on the neuropathy-free interval in patients receiving vincristine (VCR) containing chemotherapy for Hodgkin's or non-Hodgkin's lymphoma.
  • The final patient assessment was performed 1 month after discontinuation of study medication.
  • CONCLUSION: Contrary to a single previous pilot study in patients receiving VCR-based chemotherapy, in our study the ACTH (4-9) analogue Org 2766 did not provide protection from VCR-induced neuropathy.
  • [MeSH-major] Adrenocorticotropic Hormone / analogs & derivatives. Adrenocorticotropic Hormone / pharmacology. Anticonvulsants / pharmacology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Nervous System Diseases / chemically induced. Peptide Fragments / pharmacology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicology. 1988 May;49(2-3):325-9 [3376136.001]
  • [Cites] Ann Oncol. 2000 May;11(5):509-13 [10907941.001]
  • [Cites] N Engl J Med. 1990 Jan 11;322(2):89-94 [2152972.001]
  • [Cites] Cancer Res. 1973 Jun;33(6):1258-64 [4352365.001]
  • [Cites] Arch Neurol. 1992 Oct;49(10):1027-31 [1329697.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Apr;24(4):637-42 [2838292.001]
  • [Cites] J Neurooncol. 1996 Dec;30(3):173-80 [8943092.001]
  • [Cites] Neurology. 1968 Sep;18(9):875-82 [4301062.001]
  • [Cites] Muscle Nerve. 1987 Jan;10(1):80-4 [3031498.001]
  • [Cites] Electromyogr Clin Neurophysiol. 1999 Sep;39(6):323-30 [10499201.001]
  • [Cites] Neurology. 1969 Apr;19(4):367-74 [5813374.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(2):162-6 [8387400.001]
  • [Cites] J Neurol. 2002 Jan;249(1):9-17 [11954874.001]
  • [Cites] Diabetes. 1989 Feb;38(2):225-30 [2536628.001]
  • [Cites] Ann Intern Med. 1974 Jun;80(6):733-7 [4364934.001]
  • [Cites] J Comp Neurol. 2000 Sep 4;424(4):563-76 [10931481.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Oct;279(1):410-5 [8859020.001]
  • [Cites] Peptides. 1987 May-Jun;8(3):415-22 [2821519.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):191-214 [8156541.001]
  • [Cites] Brain. 1973;96(1):69-86 [4348690.001]
  • [Cites] Ann N Y Acad Sci. 1993 May 31;680:401-11 [8390160.001]
  • [Cites] Eur J Pharmacol. 2000 Sep 29;405(1-3):3-12 [11033309.001]
  • [Cites] Brain Res. 1995 Apr 10;676(2):258-67 [7613995.001]
  • [Cites] Brain Res. 1998 Jun 1;794(2):313-9 [9622663.001]
  • [Cites] Folia Neuropathol. 1995;33(1):21-4 [8673415.001]
  • [Cites] Muscle Nerve. 1989 May;12(5):353-9 [2542784.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1979 Sep;42(9):793-803 [501379.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):172-7 [9367703.001]
  • [Cites] Peptides. 1980 Summer;1(2):135-8 [6264409.001]
  • [Cites] Peptides. 1992 Jul-Aug;13(4):769-74 [1332000.001]
  • [Cites] Drugs. 1999 Mar;57(3):293-308 [10193684.001]
  • [Cites] Med Toxicol. 1986 Nov-Dec;1(6):421-7 [3540519.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):497-501 [8123480.001]
  • [Cites] Ann N Y Acad Sci. 1999 Oct 20;885:342-9 [10816665.001]
  • [Cites] Peptides. 1987 Jul-Aug;8(4):581-4 [2819831.001]
  • [Cites] Neurology. 1994 Mar;44(3 Pt 1):488-94 [8145920.001]
  • [Cites] Exp Neurol. 1987 Sep;97(3):746-50 [3040462.001]
  • [Cites] Brain. 1993 Oct;116 ( Pt 5):1059-75 [8221047.001]
  • [Cites] J Neurol. 1992 Mar;239(3):143-6 [1315383.001]
  • [Cites] Behav Brain Res. 1996 Jan;74(1-2):1-15 [8851911.001]
  • [Cites] Brain Res. 1997 Nov 7;774(1-2):20-6 [9452187.001]
  • [Cites] Hear Res. 1998 Oct;124(1-2):108-17 [9822908.001]
  • [Cites] J Neurol. 1994 Jun;241(7):432-5 [7931444.001]
  • [Cites] J Neurol Sci. 1994 Nov;126(2):109-15 [7853014.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):23-7 [8384253.001]
  • (PMID = 14727106.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Peptide Fragments; 0 / Placebos; 50913-82-1 / Org 2766; 5J49Q6B70F / Vincristine; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


18. Song DY, Jones RJ, Welsh JS, Haulk TL, Korman LT, Noga S, Goodman S, Herman M, Mann R, Marcellus D, Vogelsang G, Ambinder RF, Abrams RA: Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):166-71
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma.
  • The purpose of this study was to find the maximal tolerable dose of locoregional irradiation (LRT) between 1000 and 2000 cGy that could be integrated with our Cytoxan-total body irradiation (TBI) BMT conditioning regimen in the treatment of lymphoma.
  • METHODS AND MATERIALS: Patients had Hodgkin's or non-Hodgkin's lymphoma in chemotherapy-refractory relapse.
  • All patients received LRT to a maximum of three sets of fields encompassing either all current or all previously known sites of disease.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Maximum Tolerated Dose. Whole-Body Irradiation / methods

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909229.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


19. Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E: Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol; 2005 Sep;16(9):1524-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
  • BACKGROUND: The aim of this study was to evaluate the accuracy of computed tomography (CT) and [(18)F]fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for prediction of progression-free survival of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) patients after completion of therapy.
  • RESULTS: CT imaging results were progressive disease (PD) in five, stable disease (SD) in 57, and partial response (PR) or complete remission (CR) in 39 patients.
  • FDG-PET suggested residual lymphoma in 24 patients.
  • Three-year progression-free survival rates after exclusion of five PD patients were: 100% (PET negative; CT: PR or CR), 81% (PET negative; CT: SD), 21% (PET positive; CT: SD) and 0% (PET positive; CT: PR).
  • CONCLUSIONS: Among lymphoma patients with PR and SD on CT, FDG-PET discriminated those destined to progress into a low risk of < or =20% and a high risk for recurrence of > or =80%.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946979.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y: Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging; 2004 Jan;31(1):22-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
  • This study was designed to determine the value of 2-[fluorine-18]-fluoro-2-deoxy- d-glucose positron emission tomography (FDG-PET) in the early assessment of therapy response in lymphoma patients.
  • We studied 20 patients with pathologically proven lymphoma, including 17 patients with aggressive non-Hodgkin's lymphoma and three patients with Hodgkin's lymphoma.
  • Comparison with the baseline SUVs revealed that the responders showed a significantly greater percent reduction in SUV after 1-2 cycles of therapy as compared with the non-responders (81.2%+/-9.5% vs 35.0%+/-20.2%, P<0.001).
  • In addition, using 60% reduction as a cut-off value, the responders were clearly separated from the non-responders, with the exception of one non-responder.
  • In conclusion, when performed early during chemotherapy, FDG-PET may be predictive of clinical outcome and allows differentiation of responders from non-responders in cases of aggressive lymphoma.
  • [MeSH-major] Drug Monitoring / methods. Fluorodeoxyglucose F18. Hodgkin Disease / diagnostic imaging. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / diagnostic imaging. Lymphoma, Non-Hodgkin / drug therapy. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:177-80 [1710919.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Radiother Oncol. 1988 Feb;11(2):119-22 [3353516.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Eur J Nucl Med. 2000 Feb;27(2):176-84 [10755723.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1811-7 [7562048.001]
  • [Cites] J Nucl Med. 2001 Aug;42(8):1139-43 [11483671.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):873-8 [11920453.001]
  • [Cites] J Nucl Med. 2000 Jun;41(6):999-1005 [10855624.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):797-803 [12029554.001]
  • [Cites] Radiology. 1998 May;207 (2):431-7 [9577492.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1003-8 [10452318.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):543-53 [11342337.001]
  • [Cites] Radiology. 1992 Feb;182(2):359-63 [1732950.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1713-6 [9164176.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):302-10 [11180075.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] Radiology. 2000 Jan;214(1):253-7 [10644133.001]
  • [Cites] Blood. 1998 Jun 15;91(12 ):4464-71 [9616140.001]
  • [Cites] J Clin Oncol. 1986 Feb;4(2):160-4 [2418167.001]
  • [Cites] Blood. 2001 Nov 15;98 (10 ):2930-4 [11698273.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):931-3 [3373263.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • (PMID = 14574514.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Krawczuk-Rybak M, Solarz E, Gadomski J, Matysiak M, Wołczyński S: [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):623-30
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood].
  • AIM: To investigate testicular function (spermato- and steroidogenesis) in adolescents and young men cured of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • 2. The treatment for HL in IIb, IIIb, IV clinical stage with increasing number of therapeutic protocols, especially together with radiotherapy, led to gonadal dysfunction (increase of FSH, decrease of inhibin B values).
  • 3. The values of testosterone were normal in all patients, whereas LH was elevated in patients treated for HL (stages IIIb and IV).
  • [MeSH-major] Combined Modality Therapy / adverse effects. Gonadotropins, Pituitary / blood. Hodgkin Disease / therapy. Infertility, Male / etiology. Lymphoma, Non-Hodgkin / therapy. Spermatogenesis / drug effects. Spermatogenesis / radiation effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317893.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


22. Barr P, Fisher R, Friedberg J: The role of bortezomib in the treatment of lymphoma. Cancer Invest; 2007 Dec;25(8):766-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bortezomib in the treatment of lymphoma.
  • Among the various cancers susceptible to proteasome inhibition are the non-Hodgkin's lymphomas.
  • Mantle cell lymphoma appears to be particularly sensitive, leading to the FDA approval of bortezomib in patients who have received at least one prior therapy.
  • This demonstration of clinical efficacy has led to an explosion of research attempting to further understand the anti-tumor effect of proteasome inhibition and clinical investigations exploring bortezomib in combination with other agents.
  • In this review, we will detail the clinical results and ongoing trials utilizing bortezomib in Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use
  • [MeSH-minor] Bortezomib. Hodgkin Disease / drug therapy. Humans. Lymphoma, Mantle-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 86
  •  go-up   go-down


23. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • Thrombotic thrombocytopenic purpura and thrombosis resulting from protein S deficiency are relatively rare complications of HIV in the United States in patients taking HAART, but are frequent in the developing world where these drugs are not available.
  • Hodgkin's and non-Hodgkin's lymphoma are still problematic in patients with advanced disease with high viral loads.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


24. Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D, Meadows AT: Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol; 2001 May 01;19(9):2390-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
  • PURPOSE: To determine the toxicity and response rate in children treated with dexamethasone, etoposide, cisplatin, high-dose cytarabine, and L-asparaginase (DECAL) for recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
  • RESULTS: After two cycles of DECAL induction therapy, complete response (CR) or partial response (PR) was reported in 19 (65.5%; 10 CRs and nine PRs) of 29 patients with HD and 29 (41.6%; 23 CRs and six PRs) of 68 patients with NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331317.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


25. Divgi C: Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol; 2005 Feb;32(1 Suppl 1):S11-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging: staging and evaluation of lymphoma using nuclear medicine.
  • The management of lymphoma is dependent on accurate staging of the disease and evaluation of histology and other risk factors.
  • Nuclear medicine techniques permit the evaluation of functional status, and nuclear medicine is likely to have its greatest impact in the detection of viable tumor in persistent masses.
  • Nuclear imaging can be conducted using single photon agents, such as 67 Ga-citrate with SPECT (single photon emission computed tomography), or with positron emitters, such as 18 F-fluorodeoxyglucose (FDG) with PET (positron emission tomography).
  • Many studies have indicated that FDG-PET is as good as or better than 67 Ga-SPECT for the detection of lymphoma.
  • At present, FDG-PET scanning is not routinely available in all institutions; however, a role can be indicated for FDG-PET in several areas of lymphoma management, including initial staging, predicting response to therapy (during and following chemotherapy), and identification of residual tumor.
  • This article examines the role of the different imaging techniques available and the use of these techniques in the staging and evaluation of patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / radionuclide imaging. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786021.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Pro B, Younes A: New molecular targets for treatment of lymphoma. Curr Oncol Rep; 2004 Sep;6(5):360-8
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New molecular targets for treatment of lymphoma.
  • These discoveries helped in designing and testing novel drugs that target specific cellular pathways.
  • In this review, we focus on new molecular targets that are being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
  • [MeSH-major] Lymphoma / genetics. Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cell Proliferation. Cell Survival. Enzyme Inhibitors / pharmacology. Humans. Medical Oncology / methods. Medical Oncology / trends. Models, Biological. Models, Genetic. Proteasome Endopeptidase Complex / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Remission Induction. Thalidomide / pharmacology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Nov 1;98(9):2784-90 [11675352.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):343-8 [14667501.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):657-66 [14770419.001]
  • [Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]
  • [Cites] J Leukoc Biol. 1999 May;65(5):535-42 [10331480.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:61-5 [8172820.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):2-17 [10647992.001]
  • [Cites] Br J Haematol. 2001 May;113(2):265-74 [11380390.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):193-204 [15023437.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1186-9 [15022285.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):607-12 [12808067.001]
  • [Cites] Drug Discov Today. 2003 Apr 1;8(7):307-15 [12654543.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):363-6 [12450791.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11709-14 [9751730.001]
  • [Cites] Nat Rev Immunol. 2003 Sep;3(9):745-56 [12949498.001]
  • [Cites] Blood. 1996 Jan 1;87(1):265-72 [8547651.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2612-4 [11895803.001]
  • [Cites] Curr Drug Targets Cardiovasc Haematol Disord. 2003 Dec;3(4):261-86 [14683470.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):135-41 [9450802.001]
  • [Cites] Cell. 2001 Feb 23;104(4):487-501 [11239407.001]
  • [Cites] J Clin Invest. 1999 Oct;104(7):947-55 [10510335.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3526-34 [12972530.001]
  • [Cites] J Clin Immunol. 2003 Sep;23(5):317-32 [14601641.001]
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):171-5 [10629073.001]
  • [Cites] Blood. 1995 Feb 1;85(3):780-9 [7530508.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23 ):14363-7 [9603945.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):458-67 [12879461.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Mar;4(3):192-201 [12612638.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Jun;7(2):205-28 [14763163.001]
  • [Cites] Anticancer Res. 1990 Mar-Apr;10(2A):401-6 [1693265.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):893-900 [15010827.001]
  • [Cites] Eur J Immunol. 1995 Jul;25(7):2083-9 [7621881.001]
  • [Cites] Am J Clin Pathol. 1996 Apr;105(4):522-3 [8604696.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3370-5 [10716715.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):780-1 [7534045.001]
  • [Cites] Lancet. 1997 Apr 19;349(9059):1137-41 [9113013.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):106-13 [12953803.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1812-23 [10784621.001]
  • [Cites] J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S21-2 [19791425.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):988-90 [9230876.001]
  • [Cites] Nat Med. 2001 Feb;7(2):151-2 [11175837.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3712-8 [11090051.001]
  • [Cites] Leuk Lymphoma. 1995 Dec;20(1-2):27-38 [8750620.001]
  • [Cites] Curr Opin Oncol. 1999 Sep;11(5):364-9 [10505772.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10 (9):3207-15 [15131062.001]
  • [Cites] Int J Biol Markers. 1999 Jul-Sep;14(3):135-43 [10569134.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):371-7 [12901945.001]
  • (PMID = 15291979.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Receptors, Tumor Necrosis Factor; 4Z8R6ORS6L / Thalidomide; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 63
  •  go-up   go-down


27. Coenegrachts K, Vanbeckevoort D, Deraedt K, Van Steenbergen W: Mri findings in primary non-Hodgkin's lymphoma of the liver. JBR-BTR; 2005 Jan-Feb;88(1):17-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mri findings in primary non-Hodgkin's lymphoma of the liver.
  • Primary lymphoma of the liver is a very rare malignancy.
  • Most often, these lesions consist of diffuse large B-cell non-Hodgkin's lymphoma that occurs mostly in immunodeficient patients.
  • Secondary liver involvement during Hodgkin's and non-Hodgkin's lymphoma is frequent.
  • The present case describes the MRI features of a primary lymphoma of the liver presenting as a solitary nodule.
  • The primary lymphoma presents as a T2-hyperintense homogeneous nodule, with a signal intensity comparable with the signal intensity of the spleen.
  • Two and a half minutes after the administration of contrast agent, the lesion is iso-attenuating with the liver parenchyma.
  • It remains uncertain whether the presence of the Gamna-Gandy bodies is associated with the liver lymphoma or with the underlying sickle cell anaemia, or with a combination of both.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792163.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


28. Wedgwood A, Pro B, Younes A: The lymphomas: molecular pathways and novel therapeutic targets. Curr Hematol Rep; 2005 Jul;4(4):324-34
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These discoveries helped in designing and testing novel drugs that target specific cellular pathways.
  • In this review, we focus on new molecular targets that are currently being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD80 / therapeutic use. Antigens, Neoplasm / therapeutic use. Cell Division / drug effects. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009048.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD80; 0 / Antigens, Neoplasm; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 105
  •  go-up   go-down


33. Okada S: [Recent advances in the treatment of AIDS-related malignant lymphoma]. Nihon Rinsho; 2010 Mar;68(3):491-6
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent advances in the treatment of AIDS-related malignant lymphoma].
  • The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • However, the number of HIV-associated non-Hodgkin's lymphoma patients has increased with the increase of HIV-1 infected patients in Japan.
  • Although the evidence currently supports an intensive and curative approach for the management of HIV-associated lymphoma, we must be vigilant about adverse effects and interaction of chemotherapeutic drugs, implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229796.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 29
  •  go-up   go-down


34. Sparano JA: HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol; 2007 Sep;19(5):458-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphoma: the evidence for treating aggressively but with caution.
  • PURPOSE OF THE REVIEW: The aim of this article is to review key reports regarding the biology and management of HIV-associated lymphoma during the past year.
  • RECENT FINDINGS: The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased risk of Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • Emerging evidence suggests that patients with HIV-associated lymphoma should be treated in a similar manner as immunocompetent patients with the same disease, especially if the CD4 count is 50-100 cells/mul or higher.
  • Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy appears to result in improved control of B-cell lymphoma, but may come at the expense of an increased risk of bacterial and viral infections.
  • SUMMARY: Although the evidence currently supports an aggressive and curative approach for the management of HIV-associated lymphoma, clinicians must be vigilant about implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] HIV. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Clinical Trials as Topic. Humans


35. Serrano D, Miralles P, Balsalobre P, Díez-Martin JL, Berenguer J: Hematopoietic stem cell transplantation in patients infected with HIV. Curr HIV/AIDS Rep; 2010 Aug;7(3):175-84
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advent of highly active antiretroviral therapy made it possible to treat medical conditions in HIV-infected patients in the same way as in the general population.
  • Several studies have reported the feasibility, safety, and efficacy of autologous HSCT as rescue or consolidation treatment for non-Hodgkin's and Hodgkin's lymphoma in HIV-infected patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Hodgkin Disease / complications. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 2005 Apr;33(4):487-94 [15781340.001]
  • [Cites] J Infect Dis. 2000 Jan;181(1):148-57 [10608761.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3329-35 [8896397.001]
  • [Cites] Transplantation. 2006 Jun 27;81(12):1658-61 [16794531.001]
  • [Cites] Cancer. 1994 May 1;73(9):2400-7 [8168044.001]
  • [Cites] Med Clin (Barc). 2008 Mar 8;130(8):300-11 [18358123.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):279-84 [11882366.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jul;15(7):864-71 [19539219.001]
  • [Cites] Bone Marrow Transplant. 2010 Mar;45(3):584-6 [19617906.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Clin Infect Dis. 2000 Mar;30(3):504-10 [10722435.001]
  • [Cites] AIDS. 2002 Apr 12;16(6):865-76 [11919488.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):422-8 [18434957.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Leuk Lymphoma. 2008 Jun;49(6):1155-60 [18452074.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] AIDS Read. 2004 Jul;14(7):372-4, 377-9 [15282866.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):289-90 [10969356.001]
  • [Cites] AIDS. 2002 Sep 27;16(14):1973-6 [12351963.001]
  • [Cites] Biol Blood Marrow Transplant. 2011 Apr;17(4):586-7 [19892025.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1100-8 [15377471.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):601-2 [18410904.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):261-2 [15908966.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):27-34 [19339937.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1471-9 [11054260.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):11-5 [19339935.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] J Virol. 1999 Nov;73(11):9089-97 [10516015.001]
  • [Cites] Haematologica. 2007 Apr;92(4):e56-8 [17562594.001]
  • [Cites] Blood. 1998 Feb 1;91(3):907-15 [9446651.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):744-53 [3358573.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1069-76 [19417577.001]
  • (PMID = 20549392.001).
  • [ISSN] 1548-3576
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


36. Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A: CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Eur J Haematol; 2007 Feb;78(2):111-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
  • Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34(+) cell number.
  • Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given > or = 5 x 10(6)/kg CD34(+) cells received no G-CSF; 64 patients (group 2) given < or = 5 x 10(6)/kg CD34(+) cells received G-CSF from day +5 after stem-cell reinfusion.
  • [MeSH-major] Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cells / drug effects. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antifungal Agents / administration & dosage. Blood Transfusion. Cohort Studies. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Drug Utilization. Female. Fever / epidemiology. Fever / etiology. Filgrastim. Gastrointestinal Diseases / chemically induced. Graft Survival / drug effects. Hematopoietic Stem Cell Mobilization / methods. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Infection Control. Length of Stay / statistics & numerical data. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / drug therapy. Recombinant Proteins / administration & dosage. Recombinant Proteins / pharmacology. Rituximab. Transplantation, Autologous. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313558.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antifungal Agents; 0 / Antigens, CD34; 0 / Recombinant Proteins; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5V9KLZ54CY / Vinblastine; 6WS4C399GB / lenograstim; PVI5M0M1GW / Filgrastim; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


37. Maccormick RE: Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses; 2006;67(2):212-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is curative for a small number of malignancies including childhood leukemia, Hodgkin's and non-Hodgkin's lymphoma, and germ cell malignancies.
  • First successfully employed in the mid 1970s, adjuvant chemotherapy is associated with up to a 30% relative improvement in long-term overall survival in high risk breast cancer but demonstrates significantly less absolute improvement.
  • This complex of problems is suggestive of early onset frailty.
  • The impact of chemotherapy, particularly those agents used in the adjuvant setting, in relationship to these aging mechanisms is explored.
  • Whereas short-term toxicity of chemotherapy can usually be considered acceptable even for a small improvement in survival, long-term toxicity such as early onset frailty can have an impact on quality of life that could last for years.
  • This possible effect on aging could have implications on the decision to take adjuvant chemo, what agents to use, means to minimize the aging effect and the need to monitor for early onset frailty.
  • [MeSH-major] Aging, Premature / etiology. Chemotherapy, Adjuvant / adverse effects. Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546325.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


38. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma; 2001 Mar;1(4):298-302
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
  • DAB(389)IL-2 (denileukin diftitox, ONTAK) is a cytokine-targeted fusion protein that delivers the catalytic domain of diphtheria toxin to lymphoma cells expressing the interleukin-2 receptor (IL-2R).
  • In phase I and phase III studies of DAB(389)IL-2 in patients with cutaneous T-cell lymphoma (CTCL), non-Hodgkin's lymphoma, and Hodgkin's disease in which premedications were limited to diphenhydramine and acetaminophen, acute infusion-related hypersensitivity reactions occurred in 70% of patients and vascular leak syndrome (VLS) in 27%, resulting in discontinuation of therapy in 29% of patients.
  • [MeSH-major] Diphtheria Toxin / adverse effects. Drug Hypersensitivity / prevention & control. Glucocorticoids / therapeutic use. Immunosuppressive Agents / adverse effects. Immunotoxins / adverse effects. Interleukin-2 / adverse effects. Lymphoma, T-Cell, Cutaneous / drug therapy. Recombinant Fusion Proteins / adverse effects. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707845.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 0 / Immunotoxins; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 7S5I7G3JQL / Dexamethasone; VB0R961HZT / Prednisone
  •  go-up   go-down


39. Horneff G: [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis]. Z Rheumatol; 2010 Aug;69(6):516-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Reports on malignancies observed in children exposed to TNF-inhibitors have raised questions about a potentially increased risk for lymphoma in particular.
  • In addition, knowledge about the background incidence of malignancies in children with JIA and the influence of co-medication is limited.
  • RESULTS: Between 2001 and 2009 five cases of malignancy were documented in the German JIA Etanercept in Children Registry covering 1200 patients, including one case each of non-Hodgkin's lymphoma, Hodgkin's lymphoma, thyroid cancer, yolk sac cancer, and cervical dysplasia.
  • All five patients had been treated with a number of other drugs including cytotoxic drugs (methotrexate, leflunomide, azathioprine, cyclosporine A) before institution of etanercept therapy.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Antirheumatic Agents / therapeutic use. Arthritis, Juvenile / drug therapy. Biological Products / adverse effects. Neoplasms / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adalimumab. Adolescent. Adult. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Child. Cross-Sectional Studies. Drug Therapy, Combination. Etanercept. Germany. Humans. Immunoglobulin G / adverse effects. Immunoglobulin G / therapeutic use. Leukemia / chemically induced. Leukemia / epidemiology. Lymphoma / chemically induced. Lymphoma / epidemiology. Receptors, Tumor Necrosis Factor / therapeutic use. Registries. Risk Factors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Arthritis Rheum. 2000 Jun;29(6):348-59 [10924020.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] Z Rheumatol. 2006 Mar;65(2):152-6, 158 [16372138.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):531-3 [12688327.001]
  • [Cites] J Rheumatol. 2008 Aug;35(8):1681 [18671329.001]
  • [Cites] N Engl J Med. 2008 Aug 21;359(8):810-20 [18716298.001]
  • [Cites] Ann Rheum Dis. 2010 Apr;69(4):654-9 [19439429.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):497-502 [11054684.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1414-20 [15843454.001]
  • [Cites] J Rheumatol. 1998 Feb;25(2):366-75 [9489836.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [17255842.001]
  • [Cites] Lancet. 1998 Mar 28;351(9107):969-73 [9734957.001]
  • [Cites] Ann Rheum Dis. 2009 Apr;68(4):519-25 [18413440.001]
  • [Cites] Reumatismo. 2006 Jan-Mar;58(1):31-8 [16639486.001]
  • [Cites] Arthritis Rheum. 2006 Jun;54(6):1987-94 [16732547.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):386-8 [19274799.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):763-9 [10717011.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3096-106 [17763439.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1655-66 [15843668.001]
  • [Cites] J Rheumatol. 1986 Feb;13(1):118-23 [3517321.001]
  • [Cites] Clin Exp Rheumatol. 2006 Sep-Oct;24(5):599-605 [17181934.001]
  • [Cites] Expert Opin Pharmacother. 2009 Dec;10(18):3049-60 [19954274.001]
  • [Cites] Med Monatsschr Pharm. 2008 Sep;31(9):326-36; quiz 337-8 [18831464.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):169-78 [15979323.001]
  • [Cites] Inflamm Bowel Dis. 2007 Aug;13(8):1024-30 [17480018.001]
  • [Cites] J Rheumatol. 2008 Aug;35(8):1680-1 [18671328.001]
  • [Cites] Ann Rheum Dis. 2004 Dec;63(12):1638-44 [15115709.001]
  • [Cites] Rheumatology (Oxford). 1999 Aug;38(8):739-42 [10501423.001]
  • [Cites] Arthritis Rheum. 2009 Sep;60(9):2794-804 [19714630.001]
  • [Cites] Arch Dis Child. 1998 Apr;78(4):367-70 [9623403.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2392-401 [12355487.001]
  • [Cites] N Engl J Med. 1992 Apr 16;326(16):1043-9 [1549149.001]
  • [Cites] Ann Rheum Dis. 2004 Jul;63(7):836-42 [15194580.001]
  • [Cites] Ann Rheum Dis. 2006 May;65(5):617-22 [16249224.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):2886-95 [17729297.001]
  • [Cites] Z Rheumatol. 2009 Mar;68(2):162-4 [19214541.001]
  • [Cites] Ann Rheum Dis. 2009 May;68(5):635-41 [18413443.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):257-67 [19274777.001]
  • (PMID = 20532787.001).
  • [ISSN] 1435-1250
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Biological Products; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


40. Yang BB, Kido A, Shibata A: Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy; 2007 Oct;27(10):1387-93
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: A total of 370 patients with non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or breast cancer.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / blood. Granulocyte Colony-Stimulating Factor / therapeutic use. Neoplasms / blood. Neoplasms / drug therapy. Neutrophils / drug effects
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Dose-Response Relationship, Drug. Filgrastim. Humans. Leukocyte Count. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / drug therapy. Randomized Controlled Trials as Topic. Recombinant Proteins. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896894.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


41. Walewski J, Krzyzanowska JB, Kraszewska E, Lampka E, Romejko-Jarosińska J, Miśkiewicz Z, Meder J: CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma. Med Oncol; 2000 Aug;17(3):195-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
  • Patients with recurrent or refractory Hodgkin's and non-Hodgkin's lymphoma are increasingly being treated with high-dose therapy and hematopoietic cell transplantation.
  • Modern chemotherapy programs for Hodgkin's lymphoma include virtually all active agents and little is left for effective salvage.
  • Mitoxantrone is an active agent in lymphoma that is not generally used in first-line treatment.
  • The aim of this study was to determine toxicity and response rate to CN3OP (fractionated mitoxantrone 6 mg/m2 on days 1, 2, and 3, combined with standard dose cyclophosphamide, vincristine, and prednisone) in 44 patients with relapsed or refractory lymphoma.
  • A median of 4 cycles of CN3OP were given per patient for a total of 173 cycles.
  • Grade III-IV neutropenia occured in 53% of cycles, Grade I-III mucositis in 24%, and Grade I-III infection in 17% of cycles.
  • Of 34 evaluable patients with Hodgkin's lymphoma 12 (35%) achieved complete remission (CR) and 15 (44%) partial remission (PR) for an overall response rate of 79%.
  • Two of five evaluable non-Hodgkin's lymphoma patients responded with PR.
  • At this time 16 patients have died; 12 of lymphoma, two of unknown cause and two of other causes.
  • CN3OP is an effective and safe regimen for cytoreduction in Hodgkin's lymphoma patients pretreated with doxorubicin/alkylator/etoposide-containing primary therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 1;93(11):3632-6 [10339468.001]
  • [Cites] Semin Oncol. 1984 Sep;11(3 Suppl 1):47-9 [6484580.001]
  • [Cites] Cancer J Sci Am. 1998 Jul-Aug;4(4):254-60 [9689984.001]
  • [Cites] Bone Marrow Transplant. 1998 Aug;22(3):265-71 [9720740.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):754-61 [2016617.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):228-36 [1732423.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1071-9 [8501493.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1252-8 [1634914.001]
  • [Cites] Semin Oncol. 1984 Sep;11(3 Suppl 1):54-8 [6385266.001]
  • [Cites] Ann Oncol. 1990;1(2):123-7 [1706614.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1137-45 [8443375.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(1):51-3 [3757159.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1573-82 [7687667.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 4:105-8 [8836420.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1203-7 [2446751.001]
  • [Cites] Blood. 1999 Feb 1;93(3):761-79 [9920825.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2351-61 [8246024.001]
  • [Cites] Blood. 1997 Feb 1;89(3):801-13 [9028311.001]
  • [Cites] Ann Oncol. 1991 Jul;2(7):505-9 [1911458.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1734-41 [7602363.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(10):969-74 [9632268.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6 Suppl 10):24-7 [2259920.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6 [2420012.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):143-8 [9093722.001]
  • [Cites] Ann Oncol. 1994 May;5(5):427-32 [7521204.001]
  • [Cites] Cancer Treat Rev. 1983 Jun;10(2):103-15 [6347376.001]
  • [Cites] Am J Clin Oncol. 1988 Apr;11(2):100-3 [3282421.001]
  • [Cites] Ann Intern Med. 1979 May;90(5):761-3 [434676.001]
  • (PMID = 10962530.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CN3OP regimen
  •  go-up   go-down


42. Piura B, Rabinovich A, Shaco-Levy R, Sukenik S: Vulvar invasive squamous cell carcinoma occurring in a young woman with systemic lupus erythematosus. Eur J Gynaecol Oncol; 2005;26(1):103-5
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although several studies have demonstrated a possible relationship between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia and several solid tumors, it is still debatable whether SLE patients have an increased incidence of cancer overall.
  • It can only be speculated that the SLE itself and/or the treatment with immunosuppressive drugs provoked malignant transformation and the development of vulvar squamous cell carcinoma in such a young patient.


43. Wolf T, Densmore JJ: Pegfilgrastim use during chemotherapy: current and future applications. Curr Hematol Rep; 2004 Nov;3(6):419-23
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Once-per-cycle dosing of pegfilgrastim has been evaluated in clinical trials using myelosuppressive chemotherapy in breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematologic Neoplasms / drug therapy. Neutropenia / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Dose-Response Relationship, Drug. Filgrastim. Humans. Recombinant Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15496275.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  • [Number-of-references] 27
  •  go-up   go-down


44. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer CS, Garvin J, Nichols GL, Vahdat LH, Lo KM, Skerrett D, Bernstein D, Sharpe E, Savage DG: Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone Marrow Transplant; 2005 Sep;36(6):491-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.
  • In an effort to improve the outcome of poor-risk lymphoma patients, we evaluated a novel regimen of tandem high-dose chemotherapy (THDC) with autologous stem cell transplantation.
  • A total of 41 patients (median age 40 years, range 15-68 years) with poor-risk non-Hodgkin's lymphoma and Hodgkin's disease were enrolled.
  • This THDC regimen is feasible but with notable toxicity in heavily pretreated patients; its role in the current treatment of high-risk lymphoma remains to be determined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044139.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


45. Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R: Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol; 2002 Jul;81(7):374-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
  • We retrospectively analyzed 136 cycles of HDC and autologous HSCT in 114 patients with acute myeloid leukemia (AML, 24 cycles), non-Hodgkin's lymphoma/Hodgkin's disease (NHL/HD, 55 cycles), and multiple myeloma (MM, 57 cycles) with respect to early infectious complications.
  • There were no differences with respect to the type or incidence of infections between patients with AML, NHL/HD, and MM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Infection / etiology. Leukemia, Myeloid / surgery. Lymphoma / surgery. Multiple Myeloma / surgery. Transplantation, Autologous / adverse effects
  • [MeSH-minor] Acute Disease. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Female. Fever / drug therapy. Fever / etiology. Humans. Male. Middle Aged. Neutropenia / etiology. Retrospective Studies. Transplantation Conditioning / adverse effects. Whole-Body Irradiation / adverse effects


46. Hiraki A, Fujii N, Masuda K, Ikeda K, Tanimoto M: Genetics of Epstein-Barr virus infection. Biomed Pharmacother; 2001 Sep;55(7):369-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV is the etiologic agent of acute infectious mononucleosis and is closely associated with the genesis of Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma.
  • EBV is also implicated in a variety of other diseases, such as X-linked lymphoproliferative syndrome, T-cell non-Hodgkin's lymphoma, Hodgkin's disease, and NK-cell granular lymphoproliferative disorder.
  • Recently, lymphoepithelial carcinoma of the stomach, gastric carcinoma, pyothorax-associated lymphoma, and smooth muscle tumors were also recognized as EBV-associated diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11669499.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 41
  •  go-up   go-down


47. Katamadze NA, Lartsuliani KP, Kiknadze MP: Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin. Georgian Med News; 2009 Jan;(166):43-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with malignant blood diseases (with non-Hodgkin's, Hodgkin's lymphoma and chronic lymphatic leukaemia) and patients with idiopathic dilated cardiomyopathy were investigated.
  • Consistent dose-dependent evolution of doxorubicin cardio toxicity was observed, which eventually resulted in development of anthracycline myocardiopathy.
  • In anthracycline myocardiopathy, LV undergoes the same structural and functional mass index >120 g/m(2) and idiopathic dilated myocardiopathy: LV eccentric hypertrophy (II type LV remodelling with myocardial mass index >120 g/m(2) and relative thickness of LV posterior wall <0.44); decreased LV systolic-diastolic dimensions/volumes; LV diastolic dysfunction of the restrictive type.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiomyopathy, Dilated / chemically induced. Doxorubicin / adverse effects. Heart / drug effects. Hematologic Neoplasms / drug therapy. Stroke Volume / drug effects. Ventricular Function, Left / physiology
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Echocardiography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors


48. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E: High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant; 2004 Oct;34(7):581-7
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
  • Between January 1996 and July 2002, 72 patients with non-Hodgkin's lymphoma or Hodgkin's disease underwent high-dose chemotherapy with autologous stem cell transplant conditioned with either cyclophosphamide, etoposide, carmustine (CEB) or carmustine, etoposide, cytarabine, melphalan (BEAM) at a single institution.
  • In addition, patients treated with CEB required growth factor support for a longer time than patients treated with BEAM (P = 0.0399).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carmustine / administration & dosage. Cytarabine / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma / drug therapy. Melphalan / administration & dosage. Podophyllotoxin / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Length of Stay. Male. Middle Aged. Prognosis. Retrospective Studies. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15273714.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


49. Wong SF, Chan HO: Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy; 2005 Mar;25(3):372-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Fifty-six patients aged 18 years or older with breast cancer, lung cancer, melanoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who developed neutropenia within 4 weeks after treatment with myelosuppressive chemotherapy and who had been given five or more doses of CSF as primary or secondary prophylaxis from January 1995-March 2002.
  • [MeSH-major] Formularies, Hospital. Granulocyte Colony-Stimulating Factor / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Neutropenia / chemically induced. Neutropenia / drug therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Female. Health Care Costs. Humans. Male. Middle Aged. Neoplasms / drug therapy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pharmacotherapy. 2006 Mar;26(3):443-4; discussion 444 [16503728.001]
  • (PMID = 15843284.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


50. Chen KN, Xu SF, Gu ZD, Zhang WM, Pan H, Su WZ, Li JY, Xu GW: Surgical treatment of complex malignant anterior mediastinal tumors invading the superior vena cava. World J Surg; 2006 Feb;30(2):162-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Determining the appropriate surgery-based treatment for complicated anterior mediastinal malignancies (CAMM), especially those invading the superior vena cava (SVC) and its branches, remains a challenge for general thoracic surgeons.
  • Thymic carcinoma, teratoma, embryonal carcinoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and mixed teratoma with thymoma were diagnosed in 1 patient each.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Angiography. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / mortality. Preoperative Care. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Thymectomy / methods. Thymoma / drug therapy. Thymoma / mortality. Thymoma / pathology. Thymoma / surgery. Thymus Neoplasms / drug therapy. Thymus Neoplasms / mortality. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 Nov;6(11):1722-7 [3183702.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):95-9 [10084651.001]
  • [Cites] Semin Diagn Pathol. 1991 Feb;8(1):2-13 [2047614.001]
  • [Cites] World J Surg. 2001 Feb;25(2):204-9 [11338023.001]
  • [Cites] Ann Thorac Surg. 1996 Feb;61(2):521-4 [8572759.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):18-24 [11150432.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2000 Oct;12(4):268-77 [11154722.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):67-81 [10682772.001]
  • [Cites] Minerva Cardioangiol. 2000 Mar;48(3):79-87 [10838837.001]
  • [Cites] AJR Am J Roentgenol. 1978 Aug;131(2):239-42 [209680.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2000 Oct;12(4):278-89 [11154723.001]
  • [Cites] Ann Thorac Surg. 1991 Mar;51(3):378-84; discussion 385-6 [1998414.001]
  • [Cites] J Thorac Cardiovasc Surg. 1984 Jan;87(1):43-7 [6690858.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • (PMID = 16425072.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Marchesoni D, Driul L, Fruscalzo A, Santuz M, Calcagno A, Ianni A, Geromin A, Fanin R: [Premature ovarian failure in patients affected by oncohematological disease]. Minerva Ginecol; 2005 Oct;57(5):545-50
MedlinePlus Health Information. consumer health - Premature Ovarian Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From April 1996 to May 2002 a total of 49 fertile women affected by oncohematological diseases (Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute leukemia) and treated with chemotherapy were evaluated.
  • The differences in these groups as to menstrual cycle, blood ovarian hormones, age at diagnosis, type and dosage of chemotherapy administered were evaluated.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Primary Ovarian Insufficiency / chemically induced. Primary Ovarian Insufficiency / prevention & control
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Contraceptives, Oral / therapeutic use. Female. Gonadotropin-Releasing Hormone / analogs & derivatives. Hematologic Neoplasms / drug therapy. Humans. Longitudinal Studies. Middle Aged. Prospective Studies. Triptorelin Pamoate / therapeutic use

  • Genetic Alliance. consumer health - premature ovarian failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205599.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


52. Garabrant DH, Philbert MA: Review of 2,4-dichlorophenoxyacetic acid (2,4-D) epidemiology and toxicology. Crit Rev Toxicol; 2002 Jul;32(4):233-57
Hazardous Substances Data Bank. 2,4-D .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The scientific evidence in humans and animals relevant to cancer risks, neurologic disease, reproductive risks, and immunotoxicity of 2,4-D was reviewed.
  • Epidemiologic studies provide scant evidence that exposure to 2,4-D is associated with soft tissue sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, or any other cancer.
  • There is no evidence that 2,4-D in any of its forms activates or transforms the immune system in animals at any dose.
  • Although myotonia and alterations in gait and behavioral indices are observed after overwhelming doses of 2,4-D, alterations in the neurologic system of experimental animals are not observed with the administration of doses in the microgram/kg/day range.
  • [MeSH-minor] Animals. Carcinogenicity Tests. Case-Control Studies. Cohort Studies. Dog Diseases / chemically induced. Dog Diseases / epidemiology. Dogs. Hodgkin Disease / chemically induced. Hodgkin Disease / epidemiology. Humans. Immune System / drug effects. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / epidemiology. Mutagenicity Tests. Nervous System Diseases / chemically induced. Nervous System Diseases / epidemiology. Reproduction / drug effects. Sarcoma / chemically induced. Sarcoma / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12184504.001).
  • [ISSN] 1040-8444
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Herbicides; 2577AQ9262 / 2,4-Dichlorophenoxyacetic Acid
  • [Number-of-references] 169
  •  go-up   go-down


53. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ; 2009 Dec 08;339:b4606
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: 14,358 five year survivors of cancer diagnosed under the age of 21 with leukaemia, brain cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, neuroblastoma, soft tissue sarcoma, or bone cancer between 1970 and 1986.
  • Cardiac radiation exposure of 1500 centigray or more increased the relative hazard of congestive heart failure, myocardial infarction, pericardial disease, and valvular abnormalities by twofold to sixfold compared to non-irradiated survivors.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Saf. 2000 Apr;22(4):263-302 [10789823.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):31-7 [3581032.001]
  • [Cites] Stat Med. 1990 May;9(5):505-14 [2190287.001]
  • [Cites] Am J Cardiol. 1975 Feb;35(2):216-20 [1119380.001]
  • [Cites] Chest. 1991 Mar;99(3):538-45 [1995208.001]
  • [Cites] Am J Hematol. 1991 Mar;36(3):217-8 [1705095.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] JAMA. 1991 Sep 25;266(12):1672-7 [1886191.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):182-8 [8004574.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):881-9 [8960517.001]
  • [Cites] Am J Med Sci. 1997 Dec;314(6):399-400 [9413345.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6 [15856486.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):153-9 [15900998.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):173-85 [15896910.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):324-32 [15714447.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7685-96 [16234530.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] J Clin Epidemiol. 2006 Aug;59(8):862-7 [16828682.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3635-43 [17704413.001]
  • [Cites] Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 [18512336.001]
  • [Cites] Curr Treat Options Oncol. 2008 Feb;9(1):51-66 [18363110.001]
  • [Cites] BMC Cancer. 2008;8:141 [18492236.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2319-27 [19364957.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1191-6 [10849532.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):429-47 [11139373.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Arch Intern Med. 2001 Jan 22;161(2):277-84 [11176744.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] JAMA. 2002 Apr 10;287(14):1832-9 [11939869.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):86-92 [12116055.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):743-9 [12932613.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1108-13 [14630607.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):769-73 [14990630.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):37-44 [15162142.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [CommentIn] BMJ. 2009;339:b4691 [19996460.001]
  • (PMID = 19996459.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24 CA 55727; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / 1K12RR023247; United States / NCI NIH HHS / CA / U24 CA055727-17; United States / NCRR NIH HHS / RR / K12 RR023247-05; United States / NCRR NIH HHS / RR / K12 RR023247
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3266843
  •  go-up   go-down


54. Zsáry A, Szücs S, Keltai K, Pásztor E, Schneider T, Rosta A, Sármán P, Jánoskuti L, Fenyvesi T, Karádi I: Endothelin-1 and cardiac function in anthracycline-treated patients: a 1-year follow-up. J Cardiovasc Pharmacol; 2004 Nov;44 Suppl 1:S372-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anthracyclines are widely used chemotherapeutic agents in the treatment of lymphomas known to induce cardiomyopathy in more than 20% of patients.
  • There is increasing experimental evidence that cardiac endothelial cells regulate cardiac performance and that endothelin-1 (ET-1) is a central substance in this regulatory mechanism.
  • Twenty (seven male, aged 20-68 years) patients with Hodgkin's or non-Hodgkin's lymphoma treated with anthracycline were followed-up for 1 year.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Endothelin-1 / blood. Heart Diseases / chemically induced. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Ventricular Function, Left / drug effects
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Down-Regulation. Doxorubicin / administration & dosage. Echocardiography, Doppler. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Stroke Volume / drug effects. Time Factors. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838323.001).
  • [ISSN] 1533-4023
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; CHOP protocol
  •  go-up   go-down


55. O'Leary JJ, Kennedy M, Luttich K, Uhlmann V, Silva I, Russell J, Sheils O, Ring M, Sweeney M, Kenny C, Bermingham N, Martin C, O'Donovan M, Howells D, Picton S, Lucas SB: Localisation of HHV-8 in AIDS related lymphadenopathy. Mol Pathol; 2000 Feb;53(1):43-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include opportunistic infections that sometimes result in spindle cell pseudotumours, Kaposi's sarcoma (KS), malignant lymphoma (Hodgkin's and non-Hodgkin's), and florid reactive hyperplasia.
  • AIM: To examine whether human herpesvirus 8 (HHV-8), the aetiological agent of KS, can be localised in AIDS related lymphadenopathy and whether its appearance in such nodes is predictive of Kaposi's sarcoma development.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1984 Feb 16;310(7):462-3 [6694687.001]
  • [Cites] J Pathol. 1997 Dec;183(4):447-52 [9496262.001]
  • [Cites] Blood. 1985 Nov;66(5):1092-7 [3876855.001]
  • [Cites] J Pathol. 1985 Dec;147(4):269-80 [2935606.001]
  • [Cites] Hum Pathol. 1988 May;19(5):545-9 [3371979.001]
  • [Cites] Semin Diagn Pathol. 1988 Nov;5(4):365-75 [3064217.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):592-600 [2544632.001]
  • [Cites] J Clin Pathol. 1991 Jan;44(1):33-8 [1847709.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1181-7 [1720931.001]
  • [Cites] Am J Clin Pathol. 1993 Apr;99(4):397-401 [8475905.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):797-8; author reply 798-9 [7643890.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Blood. 1996 Jan 1;87(1):414-6 [8547672.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):542-9 [8627015.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 May 20;12(8):651-7 [8744575.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):287-97 [3893175.001]
  • (PMID = 10884921.001).
  • [ISSN] 1366-8714
  • [Journal-full-title] Molecular pathology : MP
  • [ISO-abbreviation] MP, Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Other-IDs] NLM/ PMC1186901
  •  go-up   go-down


56. Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg JR: High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Bone Marrow Transplant; 2004 May;33(10):1011-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
  • In patients with refractory lymphoma, we tested the hypothesis that high-dose chemotherapy (BEAM) without stem cell support followed by a reduced intensity (RIC) allogeneic transplant with fludarabine and 2 Gy TBI 28 days later results in tumor debulking and establishment of a graft vs lymphoma effect, with acceptable toxicity.
  • In a pilot protocol we treated 10 patients, 22-62 (median 47) years of age with high-risk or refractory Hodgkin's or non-Hodgkin's lymphoma.
  • [MeSH-major] Graft vs Tumor Effect. Lymphoma / therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Disease Progression. Drug Therapy. Female. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Neutropenia. Prognosis. Prospective Studies. Recurrence. Remission Induction. Risk. Time Factors. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15064693.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


57. Mentzer SJ, Perrine SP, Faller DV: Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis; 2001 Sep;3(3):177-85
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
  • Lymphoproliferative disorders associated with the Epstein-Barr virus (EBV) include non-Hodgkin's lymphoma, Hodgkin's lymphoma, and "post-transplant lymphoproliferative disorders" (PTLD), which occur with immunosuppression after marrow and organ transplantation.
  • Lung transplant recipients are a subset of patients at special risk for developing PTLD.
  • We have developed a strategy for the treatment of EBV-associated lymphomas/PTLD using pharmacologic induction of the latent viral TK gene and enzyme in the tumor cells, followed by treatment with ganciclovir.
  • Pathologic examination in two of three patients demonstrated complete necrosis of the EBV lymphoma, with no residual disease, following a single three-week course of the combination therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Arginine / analogs & derivatives. Arginine / pharmacology. Butyrates / pharmacology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / genetics. Lung Transplantation / adverse effects. Lymphoproliferative Disorders / etiology
  • [MeSH-minor] Antiviral Agents / pharmacology. Antiviral Agents / therapeutic use. Drug Therapy, Combination. Ganciclovir / pharmacology. Ganciclovir / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Viral / drug effects. Humans. Lung Neoplasms / etiology. Postoperative Complications / drug therapy. Postoperative Complications / virology. Tumor Cells, Cultured / drug effects. Virus Latency

  • Genetic Alliance. consumer health - Post-transplant lymphoproliferative disease.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11493400.001).
  • [ISSN] 1398-2273
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85687
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Butyrates; 94ZLA3W45F / Arginine; IK8S1P79MU / arginine butyrate; P9G3CKZ4P5 / Ganciclovir
  • [Number-of-references] 91
  •  go-up   go-down


58. Küçük NO, Aras G, Soylu A, Ozcan M, Ibis E, Dinçol D: Value of combined 67Ga and 99Tc(m)-human immunoglobulin G whole-body scanning in malignant lymphoma. Nucl Med Commun; 2001 Mar;22(3):325-9
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of combined 67Ga and 99Tc(m)-human immunoglobulin G whole-body scanning in malignant lymphoma.
  • Human immunoglobulin G labelled with 99Tc(m) (99Tc(m)-HIG) is an agent introduced for the localization of inflammatory lesions.
  • There is also a limited number of reports concerning the uptake of this agent by malignant lesions.
  • The aim of this study was to evaluate the uptake of 99Tc(m)-HIG by lymphoma.
  • Twenty-three patients (five female, 18 male) with known Hodgkin's or non-Hodgkin's lymphoma for a period of 2-6 years (mean 4.2 years) and which, by using computed tomography (CT), showed recurrence, were included in the study.
  • Using 99Tc(m)-HIG and 67Ga together in lymphoma may increase sensitivity.
  • [MeSH-major] Gallium Radioisotopes. Immunoglobulins. Lymphoma / radionuclide imaging. Radiopharmaceuticals. Technetium
  • [MeSH-minor] Adult. Aged. Female. Hodgkin Disease / radionuclide imaging. Humans. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Middle Aged. Recurrence. Reproducibility of Results. Sensitivity and Specificity. Tissue Distribution. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314766.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Immunoglobulins; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m immunoglobulin; 7440-26-8 / Technetium
  •  go-up   go-down


59. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol; 2007 Feb 10;25(5):579-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revised response criteria for malignant lymphoma.
  • PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies.
  • RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma.
  • CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
  • [MeSH-major] Clinical Trials as Topic / standards. Hodgkin Disease / pathology. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242396.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D: Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol; 2003 Mar;120(6):970-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
  • This study was designed to assess the efficacy and safety of gemcitabine, cisplatin and methylprednisolone (GEM-P) for patients with relapsed or refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma.
  • Histological subtypes were: nodular sclerosing HD (n = 10), diffuse large B cell (n = 5), T cell-rich B cell (n = 2), follicular (n = 2), mantle cell (n = 1) and enteropathy-associated T-cell lymphoma (n = 1).
  • In conclusion, GEM-P is a novel combination salvage therapy for poor-prognostic primary progressive or multiply relapsed lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cisplatin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / mortality. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Male. Methylprednisolone / administration & dosage. Middle Aged. Recurrence. Survival Rate

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648066.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


61. Hudis CA, Van Belle S, Chang J, Muenstedt K: rHuEPO and treatment outcomes: the clinical experience. Oncologist; 2004;9 Suppl 5:55-69
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasingly, anemia is being recognized as a negative prognostic and predictive factor for patients undergoing chemotherapy, radiation therapy, or a combination of these treatment modalities.
  • The results of clinical studies have shown correlations between anemia and shorter survival times in patients with a wide variety of solid tumors and hematologic malignancies, including lung, ovarian, breast, and head/neck cancers, non-Hodgkin's lymphoma, Hodgkin's disease, Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia.
  • Also, anemia has been shown to predict treatment response in patients with ovarian, cervical, and urothelial cancers, mantle cell lymphoma, and chronic lymphocytic leukemia, as well as refractory/relapsed acute myelogenous leukemia.
  • Such effects not only enhance a patient's general well-being, but may also increase their tolerance of, and willingness to undergo, full courses of their cancer therapy in a timely manner.
  • These findings support the use of epoetin alfa to achieve gains in QOL and cancer treatment outcomes in anemic cancer patients and suggest that additional studies be conducted to further investigate the potential benefits of this agent in regard to improved outcomes.
  • [MeSH-major] Anemia / drug therapy. Anemia / etiology. Erythropoietin / therapeutic use. Quality of Life
  • [MeSH-minor] Activities of Daily Living. Fatigue. Hemoglobins / analysis. Humans. Neoplasms / complications. Prognosis. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15591423.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  • [Number-of-references] 69
  •  go-up   go-down


62. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol; 2004 May 15;22(10):1864-71
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
  • PURPOSE: To assess the cardiac status of the long-term survivors and to estimate the incidence and the features of subclinical cardiotoxicity induced after conventional treatment with doxorubicin for non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • PATIENTS AND METHODS: We analyzed a group of patients who previously received doxorubicin-based chemotherapy for lymphoma.
  • Cumulative dose of doxorubicin, male sex, older age, relapse, radiotherapy (mediastinal or total-body irradiation), autologous stem-cell transplantation, high-dose cyclophosphamide, and cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia, familial history of cardiac disease, being overweight, and smoking history) were evaluated as potential risk factors for the development of cardiac dysfunction.
  • CONCLUSION: Cardiac abnormalities can occur in patients treated with doxorubicin for lymphoma in the absence of CHF, even in patients who received moderate anthracycline doses.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiomyopathies / epidemiology. Doxorubicin / adverse effects. Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15143078.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


63. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol; 2003 Feb 1;21(3):514-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
  • PATIENTS AND METHODS: An open-label, randomized, phase II study was designed to compare the effects of a single subcutaneous injection of pegfilgrastim (sustained-duration filgrastim) 100 micro g/kg per chemotherapy cycle (n = 33) with daily subcutaneous injections of filgrastim 5 micro g/kg (n = 33) in patients receiving salvage chemotherapy for relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / analogs & derivatives. Granulocyte Colony-Stimulating Factor / pharmacology. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Humans. Injections, Subcutaneous. Male. Methylprednisolone / administration & dosage. Methylprednisolone / adverse effects. Middle Aged. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12560443.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 6PLQ3CP4P3 / Etoposide; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


64. Reiser M, Bredenfeld H, Engert A, Diehl V: The role of ifosfamide in the treatment of relapsed and refractory lymphoma. Eur J Haematol Suppl; 2001 Jul;64:37-40
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ifosfamide in the treatment of relapsed and refractory lymphoma.
  • Ifosfamide is an alkylating agent with proven efficacy in the treatment of solid tumours and malignant lymphomas.
  • Because it causes only mild to moderate myelosuppression, ifosfamide is often used in combination regimens with other agents.
  • Ifosfamide has been mainly used in therapy of lymphoma as a component of salvage regimens, but high-dose ifosfamide is also effective in the mobilization of peripheral stem cells for treatment of patients with relapsed or refractory lymphoma with regimens containing autologous stem cell transplantation.
  • Based on promising data with a new combination regimen containing idarubicin, etoposide and ifosfamide (IIVP-16) in patients with poor-risk non-Hodgkin's lymphoma, we have performed a phase II study using DIZE (dexamethasone 20 mg i.v. days 1-4, idarubicin 8 mg/m2 i.v. days 1 + 2, ifosfamide 1.0 g/m2 continuous infusion (c.i.) days 1-4, and etoposide 160 mg/m2 c.i. days 1-4) in patients with relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
  • In 43 evaluable patients, the response rate was 58%, including 11 complete remissions (CR) and 14 partial remissions (PR).
  • Thus, DIZE is an effective and safe regimen for pretreated patients with aggressive lymphoma.
  • [MeSH-major] Ifosfamide / administration & dosage. Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Agents, Alkylating / toxicity. Disease-Free Survival. Humans. Recurrence. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486400.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 33
  •  go-up   go-down


65. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P: Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma; 2004 Jun;5(1):45-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
  • Management of patients with multiple-relapsed lymphoma meets with little success.
  • The optimal use of available drugs in this situation is often unknown.
  • In this study we explored the use of gemcitabine starting at a dose of 800 mg/m(2) administered at a fixed infusion rate of 10 mg/m(2) per minute with cisplatin 35 mg/m(2) intravenously, both given on day 1, and dexamethasone 20 mg daily for 4 days; the treatment was given every 2 weeks (days 1 and 15 of a 28-day cycle) for the treatment of relapsed Hodgkin's and non-Hodgkin's lymphoma.
  • Twenty-two patients with a median of 4 prior treatments were enrolled (Hodgkin's lymphoma, n = 7; B-cell non-Hodgkin's lymphoma, n = 9; T-cell non-Hodgkin's lymphoma, n = 6).
  • Responses were observed in 45% of the patients: 2 of 5 with T-cell non-Hodgkin's lymphoma (1 patient withdrew after first treatment and was evaluable only for toxicity), 4 of 7 with Hodgkin's lymphoma, and 4 of 9 with B-cell non-Hodgkin's lymphoma.
  • The coadministration of gemcitabine 800 mg over 80 minutes with low-dose cisplatin and dexamethasone is feasible and sufficiently active in a heavily pretreated patient population with lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / toxicity. Cisplatin / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / toxicity. Dexamethasone / therapeutic use. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Continental Population Groups. Female. Hodgkin Disease / drug therapy. Humans. Infusions, Intravenous. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Male. Middle Aged. Pilot Projects. Recurrence

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15245607.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 7S5I7G3JQL / Dexamethasone; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


66. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D: Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer; 2005 Apr 25;92(8):1352-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
  • There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma.
  • We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Drug Resistance, Neoplasm. Humans. Methylprednisolone / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1994;5 Suppl 2:91-5 [7515652.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):543-9 [8573532.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 [7481849.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Bone Marrow Transplant. 1997 Jul;20(1):21-6 [9232251.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):525-9 [9261520.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3264-9 [9779700.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):351-4 [10355582.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):981-90 [10362105.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):943-7 [10509156.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Ann Oncol. 2000 May;11(5):595-7 [10907954.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Biochem Pharmacol. 2001 Jun 1;61(11):1401-8 [11331076.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):786-92 [11843810.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):311-5 [12201493.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):17-21 [12504621.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):970-7 [12648066.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):621-30 [12537665.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1963-70 [12799644.001]
  • [Cites] Rev Mal Respir. 2003 Apr;20(2 Pt 1):201-6 [12844017.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] Oncology. 2004;66(3):197-200 [15218310.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):45-9 [15245607.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • (PMID = 15812553.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2361993
  •  go-up   go-down


67. Zinzani PL: Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience. Ann Oncol; 2003;14 Suppl 1:i43-5
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12736231.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 30
  •  go-up   go-down


68. Hotta T: [Standard treatment of malignant lymphoma (Hodgkin's and non-Hodgkin's lymphoma)]. Nihon Naika Gakkai Zasshi; 2001 Jun 10;90(6):997-1002
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standard treatment of malignant lymphoma (Hodgkin's and non-Hodgkin's lymphoma)].
  • [MeSH-major] Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11460390.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 6
  •  go-up   go-down






Advertisement